Literature DB >> 12004339

A role for cell-surface CSF-1 in osteoblast-mediated osteoclastogenesis.

G-Q Yao1, B H Sun, E C Weir, K L Insogna.   

Abstract

CSF-1 is required for osteoblast-mediated osteoclast formation. Osteoblasts produce soluble (sCSF-1) and cell-surface forms of CSF-1 (also known as membrane-bound CSF-1, mCSF-1) but their individual contributions to osteoclastogenesis remain unclear. Using glutaraldehyde-fixed primary murine osteoblasts as a source of mCSF-1, osteoblasts from op/op mice as a source for other osteoblast-derived osteoclastogenic factors and murine bone marrow as a source of osteoclast progenitors, osteoclast-like cells (OCL) formation was observed after 7-9 days of co-culture. In contrast, no OCL formation occurred when mCSF-1 expressed by primary murine osteoblasts was blocked by CSF-1 antibody pretreatment or when op/op osteoblasts were substituted for primary murine osteoblasts in the co-culture system. Osteoclast formation was also significantly inhibited when murine primary osteoblasts were pretreated with an antisense phosphorothioate oligonucleotide against mCSF-1. Finally, mCSF-1 and sCSF-1 were synergistic in stimulating OCL formation. These data support the conclusion that mCSF-1 plays an important role in osteoblast-mediated osteoclastogenesis within the bone microenvironment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12004339     DOI: 10.1007/s00223-001-1079-x

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  17 in total

1.  Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice.

Authors:  Gang-Qing Yao; Jian-Jun Wu; Nancy Troiano; Karl Insogna
Journal:  J Bone Miner Metab       Date:  2010-07-03       Impact factor: 2.626

2.  Both cell-surface and secreted CSF-1 expressed by tumor cells metastatic to bone can contribute to osteoclast activation.

Authors:  Kader Yagiz; Susan R Rittling
Journal:  Exp Cell Res       Date:  2009-05-08       Impact factor: 3.905

3.  Effects of spinal cord injury on osteoblastogenesis, osteoclastogenesis and gene expression profiling in osteoblasts in young rats.

Authors:  S-D Jiang; L-S Jiang; L-Y Dai
Journal:  Osteoporos Int       Date:  2006-10-12       Impact factor: 4.507

Review 4.  Extracellular Vesicle-Mediated Bone Remodeling and Bone Metastasis: Implications in Prostate Cancer.

Authors:  Kalyani C Patil; Carolina Soekmadji
Journal:  Subcell Biochem       Date:  2021

5.  Targeted expression of csCSF-1 in op/op mice ameliorates tooth defects.

Authors:  S Abboud Werner; J Gluhak-Heinrich; K Woodruff; Y Wittrant; L Cardenas; M Roudier; M MacDougall
Journal:  Arch Oral Biol       Date:  2006-11-28       Impact factor: 2.633

6.  c-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation.

Authors:  Roberta Faccio; Sunao Takeshita; Alberta Zallone; F Patrick Ross; Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

7.  Targeted overexpression of the two colony-stimulating factor-1 isoforms in osteoblasts differentially affects bone loss in ovariectomized mice.

Authors:  Gang-Qing Yao; Jian-Jun Wu; Shira Ovadia; Nancy Troiano; Ben Hua Sun; Karl Insogna
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-01-13       Impact factor: 4.310

Review 8.  Optimal management of bone metastases in breast cancer patients.

Authors:  Mh Wong; N Pavlakis
Journal:  Breast Cancer (Dove Med Press)       Date:  2011-05-02

Review 9.  Key Triggers of Osteoclast-Related Diseases and Available Strategies for Targeted Therapies: A Review.

Authors:  Haidi Bi; Xing Chen; Song Gao; Xiaolong Yu; Jun Xiao; Bin Zhang; Xuqiang Liu; Min Dai
Journal:  Front Med (Lausanne)       Date:  2017-12-20

10.  Celastrol Attenuates RANKL-Induced Osteoclastogenesis in vitro and Reduces Titanium Particle-Induced Osteolysis and Ovariectomy-Induced Bone Loss in vivo.

Authors:  Qiang Xu; Guiping Chen; Huaen Xu; Guoming Xia; Meisong Zhu; Haibo Zhan; Bin Zhang; Min Dai; Hongxian Fan; Xuqiang Liu
Journal:  Front Pharmacol       Date:  2021-06-03       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.